Goldman Sachs Downgrades HSP To Neutral

Goldman Sachs is moving to the sidelines on Hospira HSP. “Our long-term bias remains positive; however, we see better opportunities elsewhere and few near-term catalysts until the company's September 2011 analyst meeting,” Goldman Sachs writes. “In addition, we think the company will need to lower long-term targets and expect management transition to create operational volatility.” Goldman Sachs has downgraded Hospira, which closed Tuesday at $56.94, to Neutral.